Cancer Chemotherapy and Pharmacology

, Volume 62, Issue 5, pp 763–768

A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer

  • Hong Suk Song
  • Young Rok Do
  • Heung Moon Chang
  • Min Hee Ryu
  • Kyung Hee Lee
  • Yeul Hong Kim
  • Dae Sik Hong
  • Jae Yong Cho
  • Kyoung Eun Lee
  • Si Young Kim
Original Article



This open-label, multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus gemcitabine combination chemotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Patients and methods

We enrolled 63 patients who received capecitabine 830 mg/m2 orally twice daily on days 1–21 plus gemcitabine 1000 mg/m2 as a 30-min infusion on days 1, 8 and 15 every 4 weeks for up to six cycles.


A total of 14 patients had partial responses giving an overall response rate of 22% (95% confidence interval [CI] 13–34%) in the intent-to-treat population. The median time to progression and overall survival were 3.9 months (95% CI 3.5–5.7) and 7.5 months (95% CI 5.0–10.0), respectively, and 1-year survival rate was 27.1% in the intent-to-treat population. Capecitabine plus gemcitabine was well tolerated. Grade 3 hematological adverse events were neutropenia (21%) and thrombocytopenia (2%); the only grade 4 hematological events were anemia (2%) and neutropenia (6%). Non-hematological adverse events were mainly gastrointestinal events and hand–foot syndrome, which affected 16% of patients. Grade 3/4 non-hematological events were infrequent.


The combination of capecitabine plus gemcitabine appears to be active and well tolerated as first-line treatment in patients with advanced/metastatic pancreatic cancer.


Pancreatic cancer Capecitabine Gemcitabine Chemotherapy 


  1. 1.
    Kelly DM, Benjamin IS (1995) Pancreatic carcinoma. Ann Oncol 6:19–28PubMedGoogle Scholar
  2. 2.
    Niederhuber JE, Brennan MF, Menck HR (1995) The national cancer database reports on pancreatic cancer. Cancer 76:1671–1677PubMedCrossRefGoogle Scholar
  3. 3.
    Korean National Cancer Center (2001) Korean central cancer registry 22nd annual report. Available from
  4. 4.
    Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL (2000) A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 95:17–31PubMedCrossRefGoogle Scholar
  5. 5.
    Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  6. 6.
    Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281PubMedCrossRefGoogle Scholar
  7. 7.
    Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291–297PubMedCrossRefGoogle Scholar
  8. 8.
    Cassidy J, Twelves C, van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendrick J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL, on behalf of the Capecitabine Colorectal Cancer Study Group (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566–575PubMedCrossRefGoogle Scholar
  9. 9.
    Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz JJ (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20:160–164PubMedCrossRefGoogle Scholar
  10. 10.
    Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, Herrmann R (2003) Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 21:66–68PubMedCrossRefGoogle Scholar
  11. 11.
    Stathopoulos GP, Syrigos K, Polyzos A, Fountzilas G, Rigatos SK, Ziras N, Potamiannou A, Tsiakopoulos I, Androulakis N, Aravantinos G, Athanasiadis A, Papakotoulas P, Georgoulias V (2004) Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 15:224–229PubMedCrossRefGoogle Scholar
  12. 12.
    Schilsky RL, Bretucci D, Vogelzang NJ, Kindler HL, Ratain MJ (2002) Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 20:582–587PubMedCrossRefGoogle Scholar
  13. 13.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  14. 14.
    Ensign LG, Gehan EA, Kamen DS, Thall PF (1994) An optimal three-stage design for phase II clinical trials. Stat Med 13:1727–1736PubMedCrossRefGoogle Scholar
  15. 15.
    Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG (1994) Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29–34PubMedCrossRefGoogle Scholar
  16. 16.
    Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H (1999) Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17:585–592PubMedGoogle Scholar
  17. 17.
    Oettle H, Arning M, Pelzer U, Arnold D, Stroszczynski C, Langrehr J, Reitzig P, Kindler M, Herrenberger J, Musch R, Korsten FW, Huhn D, Riess H (2000) A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol 11:1267–1272PubMedCrossRefGoogle Scholar
  18. 18.
    Ren Q, Kao V, Germ JL (1998) Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 4:2811–2818PubMedGoogle Scholar
  19. 19.
    Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J, Smith D, Steward W, Harper P, Neoptomos J (2005) Phase III randomised comparison of gemcitabine (GFM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 3(supplement):12(PS12)Google Scholar
  20. 20.
    Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Korneck GV (2003) Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 14:97–104PubMedCrossRefGoogle Scholar
  21. 21.
    Tempero M, Plunkett W, van Ruiz Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408PubMedCrossRefGoogle Scholar
  22. 22.
    Nakamura K, Yamaguchi T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, Kato H, Saisho H (2005) Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 92:2134–2139PubMedCrossRefGoogle Scholar
  23. 23.
    Ng SS, Tsao MS, Nicklee T, Hedley DW (2002) Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1:777–783PubMedGoogle Scholar
  24. 24.
    Moore MJ, Glodstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, ing K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group (2007) Erlotinib plus gemcitabine compared gemcitabine alone in patients with advanced pancreatic cancer: a III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 20:1960–1966CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Hong Suk Song
    • 1
  • Young Rok Do
    • 1
  • Heung Moon Chang
    • 2
  • Min Hee Ryu
    • 2
  • Kyung Hee Lee
    • 3
  • Yeul Hong Kim
    • 4
  • Dae Sik Hong
    • 5
  • Jae Yong Cho
    • 6
  • Kyoung Eun Lee
    • 7
  • Si Young Kim
    • 8
  1. 1.Division of Hematooncology, Department of Internal Medicine, Dongsan Medical CenterKeimyung University School of MedicineDaeguSouth Korea
  2. 2.Department of Internal Medicine, Asan Medical CenterUniversity of UlsanSeoulSouth Korea
  3. 3.Department of Internal MedicineYeungNam University Medical CenterDaeguSouth Korea
  4. 4.Department of Internal MedicineKorea University Anam HospitalSeoulSouth Korea
  5. 5.Department of Internal MedicineSoonChunHyang University HospitalSeoulSouth Korea
  6. 6.Department of Internal MedicineYongDong Severance HospitalSeoulSouth Korea
  7. 7.Department of Internal MedicineEwha Womans University Mokdong HospitalSeoulSouth Korea
  8. 8.Department of Internal MedicineKyungHee University HospitalSeoulSouth Korea

Personalised recommendations